

## Supplementary tables and/or figures - Individual patient data meta-analysis on continued use of glucocorticoids after their use as bridging therapy in patients with rheumatoid arthritis

Supplementary table 1. Number of patients per analysis						
(Reference category)	Age at baseline	Being female (male)	ACPA positivity (ACPA negative)	Oral GC bridging (no oral bridging)	Initial co-treatment with multiple csDMARDs (only MTX co-treatment)	Initial GC dose (effect per additional mg)
<i>GC status after bridging*</i>						
1 month	388	388	383	331	388	331
3 months	1569	1569	1473	1569	1489	1510
6 months	1024	1024	930	1024	1024	965
12 months	914	914	899	914	914	855
18 months	786	786	774	786	786	727
<i>Mean cumulative GC dose (mg) at</i>						
6 months	619	619	605	619	538	562
12 months	1544	1544	1448	1544	1463	1487
18 months	369	369	364	369	369	369
<i>Continuous GC use** (%) within</i>						
12 months	1590	1590	1488	1590	1509	1531
24 months	1457	1457	1436	1457	1376	1455
<i>Flare after<sup>Ω</sup></i>						
1 <sup>st</sup> GC bridging stop attempt (%)	952	952	869	952	952	934
<i>Flare after<sup>Ω</sup></i>						
stop attempt first GC course after bridging had ended	200	200	200	195	172	195
DMARD added after flare on stopping GC bridging (%)	134	134	99	132	134	133
<i>Abbreviations:</i> CI=confidence interval; csDMARD=conventional synthetic disease modifying antirheumatic drug; GC=glucocorticoids; mg=milligrams; MTX=methotrexate; OR=odds ratio.						